Immune Profiling for Cancer Immunotherapy Response
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorDartmouth-Hitchcock Medical Center
About this trial
In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.
Eligibility criteria
Qualifiers
Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).
Disqualifiers
Pregnant women/fetuses/neonates
Prisoners
Decision-impaired individuals
Trial design
Treatments tested in this trial
- Methylation Cytometry
Treatment groups
1,500 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov